Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Auspex Pharmaceuticals has appointed Ronald Newbold as its new chief business officer; Andreas Sommer as vice president of operations and Tadimeti Rao as vice president of preclinical development.
Subscribe to our email newsletter
Most recently, Dr Newbold was senior vice president of business development at Celldex Therapeutics. Dr Newbold holds an MBA from Columbia University and received his PhD in organic chemistry from the University of Rochester.
Dr Sommer joins the company following a successful 20-year career as a senior executive within both public and private biotechnology firms where he provided both executive operational and research leadership. Dr Sommer has received his PhD in microbiology from the University of California, Davis.
Dr Rao joins Auspex from Kalpsys where he was director of pharmacology and preclinical development. Dr Rao holds a PhD in neurochemistry-pharmaceutical sciences from the University of Alberta, Edmonton, Canada.
Mike Grey, president and CEO of Auspex, said: “We are extremely pleased to add three senior executives with the wealth of expertise offered by Ron, Andreas, and Rao. Their collective experience at both emerging biotechnology and major pharmaceutical firms will be invaluable to Auspex as we grow our pipeline, advance more drug candidates into the clinic and actively seek partners for the further development and commercialization of our products.”